Predicted to enable DNA binding activity; DNA-binding transcription factor activity, RNA polymerase II-specific; and chromatin binding activity. Predicted to be involved in several processes, including positive regulation of synaptic transmission; regulation of DNA-templated transcription; and smooth muscle tissue development. Predicted to act upstream of or within several processes, including kidney development; positive regulation of smooth muscle cell differentiation; and sensory perception of touch. Located in growth cone. Orthologous to human TSHZ3 (teashirt zinc finger homeobox 3); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil; acrylamide.
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TSHZ3 mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of TSHZ3 gene
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TSHZ3 mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of TSHZ3 gene
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of TSHZ3 mRNA, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of TSHZ3 gene
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ3 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ3 mRNA